esophageal cancer
Lucid Diagnostics Raises $16.1M in Public Offering
The firm raised the money last week in a public offering of 14,375,000 common shares, and it will use the money for working capital and general corporate purposes.
The firm believes its platform, which uses a swallowable capsule sample collection device, can improve the identification and care of patients with esophageal pre-cancer.
Lucid Diagnostics Q4 Revenues Rise 20 Percent
The firm's full-year 2024 revenues increased 79 percent year over year to $4.3 million.
Lucid Diagnostics to Raise $15.3M in Registered Direct Offering
The firm intends to use the net proceeds from the offering for working capital and other general corporate purposes.
Researchers Receive $8M NIH Grant to Evaluate Lucid Diagnostics Esophageal Precancer Test
The researchers will conduct a five-year study to evaluate the firm's collection device and test in patients without symptoms of chronic gastroesophageal reflux disease.